Display options
Cite
Ravegnini G, Sammarini G, Serrano C, et al. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Ther Adv Med Oncol. 2019;11:1758835919831902doi: 10.1177/1758835919831902.
Ravegnini, G., Sammarini, G., Serrano, C., Nannini, M., Pantaleo, M. A., Hrelia, P., & Angelini, S. (2019). Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Therapeutic advances in medical oncology, 111758835919831902. https://doi.org/10.1177/1758835919831902
Ravegnini, Gloria, et al. "Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors." Therapeutic advances in medical oncology vol. 11 (2019): 1758835919831902. doi: https://doi.org/10.1177/1758835919831902
Ravegnini G, Sammarini G, Serrano C, Nannini M, Pantaleo MA, Hrelia P, Angelini S. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Ther Adv Med Oncol. 2019 Mar 01;11:1758835919831902. doi: 10.1177/1758835919831902. eCollection 2019. PMID: 30854029; PMCID: PMC6399766.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Med Oncol. 2019 Mar 01;11:1758835919831902. doi: 10.1177/1758835919831902. eCollection 2019.

Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors.

Therapeutic advances in medical oncology

Gloria Ravegnini, Giulia Sammarini, César Serrano, Margherita Nannini, Maria A Pantaleo, Patrizia Hrelia, Sabrina Angelini

Affiliations

  1. Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
  2. Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  3. Department of Specialized, Experimental and Diagnostic Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  4. Department of Pharmacy and Biotechnology, Via Irnerio 48, 40126 Bologna, Italy.

PMID: 30854029 PMCID: PMC6399766 DOI: 10.1177/1758835919831902

Abstract

In recent years, growing research interest has focused on the so-called liquid biopsy. A simple blood test offers access to a plethora of information, which might be extremely helpful in understanding or characterizing specific diseases. Blood contains different molecules, of which circulating free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and extracellular vesicles (EVs) are the most relevant. Conceivably, these molecules have the potential for tumor diagnosis, monitoring tumor evolution, and evaluating treatment response and pharmacological resistance. This review aims to present a state-of-the-art of recent advances in circulating DNA and circulating RNA in gastrointestinal stromal tumors (GISTs). To date, progress in liquid biopsy has been scarce in GISTs due to several issues correlated with the nature of the pathology. Namely, heterogeneity in primary and secondary mutations in key driver genes has greatly slowed the development and application in GISTs, unlike in other tumor types in which liquid biopsy has already been translated into clinical practice. However, meaningful novel data have shown in recent years a significant clinical potential of ctDNA, CTCs, EVs and circulating RNA in GISTs.

Keywords: CTCs; GIST; circulating tumor cell; ctDNA; epigenetics; gastrointestinal stromal tumor; liquid biopsy; personalized medicine; precision medicine; soft tissue sarcoma

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

  1. Cancer Res. 2001 Feb 15;61(4):1659-65 - PubMed
  2. Science. 2002 Jul 5;297(5578):63-4 - PubMed
  3. N Engl J Med. 2002 Aug 15;347(7):472-80 - PubMed
  4. J Clin Oncol. 2004 Sep 15;22(18):3813-25 - PubMed
  5. Cancer Res. 2004 Oct 1;64(19):7045-9 - PubMed
  6. Clin Cancer Res. 2006 Mar 15;12(6):1743-9 - PubMed
  7. Br J Cancer. 2006 May 22;94(10):1492-5 - PubMed
  8. Lancet. 2006 Oct 14;368(9544):1329-38 - PubMed
  9. Nat Rev Cancer. 2007 Nov;7(11):834-46 - PubMed
  10. J Pathol. 2008 Sep;216(1):64-74 - PubMed
  11. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  12. J Clin Oncol. 2008 Nov 20;26(33):5360-7 - PubMed
  13. Nat Rev Genet. 2009 Mar;10(3):155-9 - PubMed
  14. Oncol Rep. 2009 Jun;21(6):1359-66 - PubMed
  15. Nat Rev Immunol. 2009 Aug;9(8):581-93 - PubMed
  16. Int J Cancer. 2009 Dec 15;125(12):2991-4 - PubMed
  17. Int J Cancer. 2011 Jun 1;128(11):2572-80 - PubMed
  18. Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S25-43 - PubMed
  19. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8 - PubMed
  20. Nat Cell Biol. 2011 Apr;13(4):423-33 - PubMed
  21. Cell Mol Life Sci. 2011 Aug;68(16):2667-88 - PubMed
  22. J Transl Med. 2011 May 23;9:75 - PubMed
  23. Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77 - PubMed
  24. Nat Rev Cancer. 2011 Nov 17;11(12):865-78 - PubMed
  25. J Clin Oncol. 2012 Jul 1;30(19):2401-7 - PubMed
  26. Ann Oncol. 2012 Nov;23(11):2937-42 - PubMed
  27. Nature. 2012 Jun 28;486(7404):532-6 - PubMed
  28. Nature. 2012 Jun 28;486(7404):537-40 - PubMed
  29. Pharmacol Ther. 2012 Nov;136(2):169-74 - PubMed
  30. J Cell Biol. 2013 Feb 18;200(4):373-83 - PubMed
  31. Nature. 2013 Mar 21;495(7441):384-8 - PubMed
  32. Nat Rev Genet. 2013 Apr;14(4):295-300 - PubMed
  33. N Engl J Med. 2013 Mar 28;368(13):1199-209 - PubMed
  34. Nature. 2013 May 2;497(7447):108-12 - PubMed
  35. Pharmacogenomics. 2013 Jun;14(8):941-56 - PubMed
  36. Clin Cancer Res. 2013 Sep 1;19(17):4854-67 - PubMed
  37. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84 - PubMed
  38. Ann Oncol. 2013 Nov;24(11):2766-72 - PubMed
  39. Genome Med. 2013 Aug 13;5(8):70 - PubMed
  40. Cell. 2013 Sep 12;154(6):1190-3 - PubMed
  41. Cancer Res. 2013 Nov 1;73(21):6384-8 - PubMed
  42. Nat Rev Genet. 2014 Jan;15(1):56-62 - PubMed
  43. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):711-6 - PubMed
  44. J Clin Oncol. 2015 Aug 1;33(22):e93-6 - PubMed
  45. Chembiochem. 2014 May 5;15(7):923-8 - PubMed
  46. Mod Pathol. 2015 Jan;28(1):4-13 - PubMed
  47. CA Cancer J Clin. 2014 Sep-Oct;64(5):311-36 - PubMed
  48. Ann Oncol. 2014 Nov;25(11):2272-7 - PubMed
  49. Cell. 2014 Aug 28;158(5):1110-1122 - PubMed
  50. Adv Drug Deliv Rev. 2015 Jan;81:75-93 - PubMed
  51. Eur J Hum Genet. 2015 Jun;23(6):817-23 - PubMed
  52. Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11 - PubMed
  53. Cancers (Basel). 2014 Dec 16;6(4):2369-86 - PubMed
  54. Gut. 2016 Apr;65(4):625-34 - PubMed
  55. Target Oncol. 2015 Dec;10(4):597-601 - PubMed
  56. Oncotarget. 2015 May 10;6(13):10697-711 - PubMed
  57. Front Immunol. 2015 May 04;6:203 - PubMed
  58. Cell Res. 2015 Aug;25(8):981-4 - PubMed
  59. Int J Mol Sci. 2015 Jul 09;16(7):15592-608 - PubMed
  60. Biochim Biophys Acta. 2016 Jan;1859(1):200-8 - PubMed
  61. Epigenomics. 2015;7(6):1033-49 - PubMed
  62. Adv Exp Med Biol. 2015;867:341-67 - PubMed
  63. Nat Commun. 2015 Nov 04;6:8760 - PubMed
  64. Mol Med. 2015 Oct 27;21 Suppl 1:S25-31 - PubMed
  65. Oncology. 2016;90(2):112-7 - PubMed
  66. Mol Oncol. 2016 Mar;10(3):374-94 - PubMed
  67. Cancer Lett. 2016 May 1;374(2):216-23 - PubMed
  68. Cancer Discov. 2016 May;6(5):479-91 - PubMed
  69. J Clin Invest. 2016 Apr 1;126(4):1208-15 - PubMed
  70. Mol Biosyst. 2016 May 24;12(6):1818-30 - PubMed
  71. Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):733-42 - PubMed
  72. Oncotarget. 2016 Jun 14;7(24):36645-36654 - PubMed
  73. Mol Diagn Ther. 2016 Aug;20(4):347-51 - PubMed
  74. Mol Cancer. 2016 May 17;15(1):39 - PubMed
  75. Development. 2016 Jun 1;143(11):1838-47 - PubMed
  76. Eur J Cancer. 2016 Aug;63:97-104 - PubMed
  77. Histochem Cell Biol. 2016 Nov;146(5):557-567 - PubMed
  78. Epigenomics. 2016 Oct;8(10):1347-1366 - PubMed
  79. Angiogenesis. 2017 Feb;20(1):139-148 - PubMed
  80. Cancer Cell. 2016 Dec 12;30(6):836-848 - PubMed
  81. Mol Diagn Ther. 2017 Jun;21(3):259-268 - PubMed
  82. Autophagy. 2017 Mar 4;13(3):452-463 - PubMed
  83. Mol Cancer Res. 2017 May;15(5):553-562 - PubMed
  84. Wiley Interdiscip Rev RNA. 2017 Jul;8(4): - PubMed
  85. Cancer Cell. 2017 Feb 13;31(2):172-179 - PubMed
  86. Cell Physiol Biochem. 2017;41(2):755-768 - PubMed
  87. Nat Rev Cancer. 2017 Apr;17(4):223-238 - PubMed
  88. Int J Clin Oncol. 2017 Jun;22(3):421-430 - PubMed
  89. Nat Rev Clin Oncol. 2017 Sep;14(9):531-548 - PubMed
  90. Target Oncol. 2017 Jun;12(3):277-288 - PubMed
  91. Genet Med. 2017 Dec;19(12):1332-1337 - PubMed
  92. Front Mol Biosci. 2017 Jun 06;4:38 - PubMed
  93. Mol Oncol. 2017 Dec;11(12):1673-1686 - PubMed
  94. J Thorac Dis. 2017 Oct;9(Suppl 13):S1346-S1358 - PubMed
  95. Mol Cell Proteomics. 2018 Mar;17(3):495-515 - PubMed
  96. Mol Cancer. 2018 Jan 17;17(1):8 - PubMed
  97. Target Oncol. 2018 Apr;13(2):175-187 - PubMed
  98. J Pathol. 2018 Apr;244(5):616-627 - PubMed
  99. Int J Mol Sci. 2018 Jan 30;19(2):null - PubMed
  100. Genomics Proteomics Bioinformatics. 2018 Feb;16(1):50-62 - PubMed
  101. Eur Urol. 2018 Sep;74(3):283-291 - PubMed
  102. Clin Cancer Res. 2018 Jun 15;24(12):2944-2950 - PubMed
  103. Oncotarget. 2018 Feb 14;9(17):13870-13883 - PubMed
  104. Cancer Genet. 2018 Dec;228-229:169-179 - PubMed
  105. PLoS One. 2018 Apr 9;13(4):e0195272 - PubMed
  106. FEBS Lett. 2018 Sep;592(17):2874-2883 - PubMed
  107. Nat Rev Clin Oncol. 2018 Sep;15(9):541-563 - PubMed
  108. Clin Transl Med. 2018 May 31;7(1):14 - PubMed
  109. Mol Cancer Ther. 2018 Nov;17(11):2473-2480 - PubMed
  110. Pharmacogenomics J. 2018 Sep 20;:null - PubMed
  111. Adv Exp Med Biol. 2018;1087:109-117 - PubMed
  112. BMC Med. 2018 Oct 2;16(1):166 - PubMed
  113. Biochem Soc Trans. 2018 Oct 19;46(5):1137-1146 - PubMed
  114. Comput Struct Biotechnol J. 2018 Oct 09;16:370-378 - PubMed
  115. Nat Rev Genet. 2019 Feb;20(2):71-88 - PubMed
  116. Micromachines (Basel). 2018 Jul 14;9(7):null - PubMed

Publication Types